Private Advisor Group LLC lessened its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 23.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 218,513 shares of the biopharmaceutical company’s stock after selling 66,881 shares during the period. Private Advisor Group LLC’s holdings in Bristol-Myers Squibb were worth $12,221,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. Tradewinds Capital Management LLC boosted its position in shares of Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares in the last quarter. Blue Chip Partners Inc. boosted its position in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares in the last quarter. Proficio Capital Partners LLC boosted its position in shares of Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 504 shares in the last quarter. American National Bank boosted its position in shares of Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares in the last quarter. Finally, Heritage Trust Co acquired a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $123,000. Hedge funds and other institutional investors own 68.97% of the company’s stock.
Bristol-Myers Squibb Company (BMY) opened at $61.43 on Monday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The firm has a market cap of $100,542.48, a price-to-earnings ratio of 20.75, a P/E/G ratio of 2.42 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the prior year, the business earned $0.77 EPS. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. analysts expect that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.
Several equities analysts recently commented on BMY shares. Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. Goldman Sachs Group Inc reissued a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. SunTrust Banks, Inc. raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective for the company in a research note on Wednesday, November 1st. Finally, Barclays PLC increased their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, October 13th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $64.93.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Private Advisor Group LLC Has $12.22 Million Holdings in Bristol-Myers Squibb Company (BMY)” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://transcriptdaily.com/2017/11/27/private-advisor-group-llc-has-12-22-million-holdings-in-bristol-myers-squibb-company-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.